Results 161 to 170 of about 112,622 (301)

RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer. [PDF]

Sci Rep
Yoshida H, Li J, Inui H, Rokugawa K, Fujiwara K.   +4 more
europepmc   +1 more source

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

PARP inhibitors' revival [PDF]

Nature Biotechnology, 2014
openaire   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

Surgical Timing and Survival in Advanced High-Grade Serous Ovarian Cancer in the PARP Inhibitor Era. [PDF]

Cancers (Basel)
Kanno M, Fusegi A, Miyazaki N, Ozawa R, Netsu S, Aoki Y, Omi M, Nomura H, Yunokawa M, Kanao H.   +9 more
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Clinical approaches to overcome PARP inhibitor resistance. [PDF]

Mol Cancer
Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, Guan Z, Li X, Tang H.   +8 more
europepmc   +1 more source

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

Cancer Science, EarlyView.
Nucleoside analogs interfere with DNA replication either by their chain‐terminating properties or by serving as DNA damage on the template. The genome maintenance pathways required to maintain cellular tolerance to each nucleoside analog vary depending on the drug.
Ryotaro Kawasumi, Rubaiat E. Tabassum, Kouji Hirota   +2 more
wiley   +1 more source

Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications. [PDF]

Cancer Med
Lin DI, Lawrence E, Danziger N, Ye H, Decker B, Gjoerup O, Graf RP, Ross JS, Huang RSP, Elvin JA, Mata DA, McKay RR.   +11 more
europepmc   +1 more source